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Objective: Although associations between testosterone and cardiovascular (CV) morbidity in women
have been proposed, no large prospective study has evaluated potential associations between
testosterone and mortality in women. The objective was to determine whether baseline testosterone
levels in women are associated with future overall or CV morbidity and mortality.
Design: Prospective cohort study with a 4.5-year follow-up period.
Methods: From a representative sample of German primary care practices, 2914 female patients
between 18 and 75 years were analyzed for the main outcome measures: CV risk factors, CV diseases,
and all-cause mortality.
Results: At baseline, the study population was aged 57.96G14.37 years with a mean body mass index
of 26.71G5.17 kg/m2. No predictive value of total testosterone for incident CV risk factors or CV
diseases was observed in logistic regressions. Patients with total testosterone levels in the lowest
quintile Q1, however, had a higher risk to die of any cause or to develop a CV event within the follow-up
period compared to patients in the collapsed quintiles Q2–Q5 in crude and adjusted Cox regression
models (all-cause mortality: Q2–Q5 versus Q1: crude hazard ratios (HR) 0.49, 95% confidence interval
(CI) 0.33–0.74; adjusted HR 0.62, 95% CI 0.42–0.939; CV events: Q2–Q5 versus Q1: crude HR 0.54,
95% CI 0.38–0.77; adjusted HR 0.68, 95% CI 0.48–0.97). Kaplan–Meier curves revealed similar data.
Conclusions: Low baseline testosterone in women is associated with increased all-cause mortality and
incident CV events independent of traditional risk factors.
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Men have a higher risk of cardiovascular (CV) morbidity
and mortality than women, and it has been
hypothesized that high testosterone levels in women
may be a critical factor exerting detrimental effects on
the CV system (1). This is supported by findings from
cross-sectional and few longitudinal studies, in which
positive associations between total and/or bioavailable
testosterone and insulin, insulin resistance, overweight,
glucose, hemostatic and inflammatory markers, carotid
artery intimal-medial thickness, and adverse lipid
profiles have been reported (2–7). Also subjects with
higher testosterone have higher risk for disease entities
such as the metabolic syndrome (MS), type 2 diabetes
mellitus (T2DM), and coronary artery disease (CAD) inndocrinologycross-sectional and case–control studies as well as a few
longitudinal studies (8–14).
Other studies did not report any significant relation-
ships or have suggested a positive effect of testosterone
on CV diseases in women. Golden, for instance, reported
associations with insulin resistance, but did not find
any association of increasing quartiles of bioavailable
testosterone with T2DM in 1973 postmenopausal
women after adjusted analyses (5). Bernini et al. (15)
reported that higher androgen concentrations in
women are related to lower carotid wall thickness, a
proxy of carotid artery atherosclerosis, independent of
other CV risk factors, and the only published prospective
study on endogenous sex hormones and CV disease and
ischemic heart disease death in postmenopausal
women, the Rancho Bernardo study, reports noDOI: 10.1530/EJE-10-0307
Online version via www.eje-online.org
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on these outcomes during 19 years of follow-up
period (16).
In a recent study, Tivesten et al. (17) reported a nearly
doubled risk of death (hazard ratios (HR) 1.96, 95%
confidence interval (CI) 1.46–2.62) in men with low
testosterone (quartile 1 versus quartiles 2–4) (17). To
our knowledge, our study is the largest prospective
study investigating the relationship of testosterone with
overall mortality in women.Subjects and methods
Study population
This study was performed as a prospective cohort study
within the DETECT cohort (Diabetes Cardiovascular
Risk-Evaluation: Targets and Essential Data for Commit-
ment of Treatment; http://www.detect-studie.de), a
large-scale, cross-sectional study with a 4.5-year
prospective–longitudinal component (55 518 unse-
lected patients, 59% women and 41% men, of 3188
primary care physicians) as previously described.
The DETECT study received the approval of the
ethics committee of the Carl Gustav Carus Medical
faculty at the Technical University of Dresden (AZ:
EK149092003; Date: 16.09.2003), and all patients
gave written informed consent. Methods and design
were presented in detail elsewhere (18–20). Blood
samples were taken from a random subset of these
patients (nZ7519) in 2003 to investigate a wide range
of laboratory markers. For the laboratory subsample,
a comprehensive 4.5-year follow-up period was
conducted in 2007/2008. Testosterone levels were
available in a random subsample of 2914 women who
were finally included in this analysis.
In general, DETECT study attrition could be kept
low (93.9 and 93.1% primary response rates) due to
several measures in place such as payments for
complete documentation and a systematic patient
tracking system to monitor critical outcomes such as
hospitalization or mortality. Therefore, information
bias due to patient dropout should be low, and
misclassification of the hard outcomes such as death
should be minimized.Assessment of CV risk factors, CV diseases, and
covariates
Clinical assessments were conducted using i) standar-
dized patient questionnaires, and ii) standardized
clinical interview and assessments of physicians with
regard to the presence and severity of a wide range of
illnesses as previously described (20).
All information was gathered at baseline and at
follow-up periods (in 2003, 2004, and 2007/2008).www.eje-online.orgPhysicians were asked to diagnose diabetes mellitus,
hyperlipidemia, hypertension, CAD, and other diag-
noses using standardized questionnaires as previously
described (20). Current medication with a focus on CV
treatments was recorded. A total of 23 medications
could be marked, including one checkbox for further
medication (20).
The behavioral variables such as smoking status
(coded as current smoker, ex-smoker, and non-smoker
as well as numbers of cigarettes per day), physical
activity (coded as less or more than 2 h/week), and
alcohol consumption (reported as numbers of drinks
per week) were based on patients’ interview assessments
at baseline as previously described (18, 20, 21).
Physicians were instructed to measure weight,
height, blood pressure, and waist circumference (WC)
according to a standardized protocol as previously
described (21). Systolic (SBP) and diastolic blood
pressure (DBP) was measured by indirect cuff sphygmo-
manometry after several minutes of rest in a sitting
position. Use of an appropriate cuff size was advised.
WC was measured with a tape measure midway
between the lowest rib and the pelvis. The following
anthropometric parameters were calculated: body mass
index (BMI, weight in kg divided by the square of
height in meters) and waist-to-height ratio (WHtR, WC
divided by measured height in cm) as previously
described (18, 20–22).
According to the guidelines of the WHO (WHO, 2000
EK IV; EASO, 2002 EK IV) and the German guidelines of
the Deutsche Adipositas Gesellschaft (DAG), Deutsche
Diabetes Gesellschaft (DDG), Deutsche Gesellschaft
fu¨r Erna¨hrung (DGE), and Deutsche Gesellschaft fu¨r
Erna¨hrungsmedizin (DGEM), a WHtR of O0.54 was
defined as abnormal, indicating visceral obesity.
MS was defined according to the International
Diabetes Federation (IDF). For the IDF classification,
criterion No. 1 and criteria Nos 2–5 needed to be
fulfilled for women: 1, WC R80 cm; 2, triglycerides
O150 mg/dl or intake of lipid-reducing therapy;
3, high-density lipoprotein cholesterol (HDL-C)
!50 mg/dl or intake of lipid-reducing therapy;
4, SBPR130 mmHg or DBPR85 mmHg or intake of
hypertensive drugs; 5, fasting glucose R100 mg/dl or
type 2 diabetes or intake of oral antidiabetics (www.idf.
org/metabolic_syndrome). T2DM was defined as fasting
blood glucose level R126 mg/dl or non-fasting blood
glucoseR200 mg/dl or intake of oral antidiabetic drugs.
All measured variables were used as continuous and/
or dichotomized variable as appropriate in this study.Assessment of death
Death was recorded by the primary care physicians.
The causes of death were collected, based on the
information of the physician and by death certificate
if available. Dates were defined by the date of death on
the physicians report. Any CV event was defined as
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percutaneous transluminal coronary angioplasty,
bypass, surgery, stroke, transient ischemic attack, or
CV death.Laboratory variables
Blood samples were collected between 0800 and
1000 h and shipped by courier at room temperature
within 24 h to the central laboratory at the Medical
University of Graz (Austria). On arrival in the central
laboratory, the samples were centrifuged immediately,
and within another 24 h, serum and plasma were
stored atK20 8C until further processing. Testosterone
was determined in serum with an electrochemilumines-
cence immunoassay (Elecsys Autoanalyzer 2010,
Modular analytics, Roche Diagnostics). The intra- and
inter-assay coefficients of variation (CV) were 2.7 and
5.6% respectively. The measuring range of the testoster-
one assay was between 0.02 and 15 ng/ml (eight
patients had testosterone levels of 0.02 ng/ml: none of
the subjects had testosterone levels below 0.02 ng/ml).
Immunological methods are commonly used to
measure testosterone (13, 14). Our assay has been
calibrated against gas chromatography–mass spec-
trometry (GC–MS) by the producer showing a strong
positive correlation (rZ0.997; documentation Roche).
Additionally, we performed a comparison study for
testosterone in women in our own laboratory. The
correlation between a liquid chromatography–mass
spectrometry (LC–MS technique) and the Elecsys
Autoanalyzer 2010 was rZ0.83 (Fig. 1).
IGF1 was determined with an automated chemi-
luminescence system (Nichols Institute Diagnostics, San
Clemente, CA, USA). The maximal intra- and inter-
assay CV were 5 and 7% respectively.
Clinical chemical parameters such as albumin
as well as cholesterol and triglycerides were determined
on a Roche Modular automatic analyzer. Lipoproteins
(HDL-C, low-density lipoprotein cholesterol (LDL-C),
and very low-density lipoprotein cholesterol (VLDL-C))
were determined electrophoretically on the HELENA0
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Figure 1 Correlation of Elecsys LC–MS/MS for testosterone in
women in DETECT laboratory.SAS-3/SAS-4 system. HbAlc was determined chromato-
graphically on an ADAMS HA 8160 analyzing system
(ARKRAY Inc., Kyoto, Japan). For all the parameters,
reagents and secondary standards were used as
recommended by the manufacturers. Inter-assay CV of
these methods are provided elsewhere (20).Statistical analysis
Women were stratified according to testosterone
quintiles at baseline (testosterone quintiles:
Q1, 0.020–0.237 ng/ml; Q2, 0.238–0.343 ng/ml; Q3,
0.344–0.472 ng/ml; Q4, 0.473–0.655 ng/ml; Q5,
0.657–9.340 ng/ml). Quintiles were used for better
discrimination given that increased n value allowed us
to do so. Further analyses were performed (i) contrast-
ing Q2–Q5 against Q1. At baseline, 11.2% presented
with elevated total testosterone levels (total testosterone
O0.82 ng/ml as defined by Roche Diagnostics) over
all age groups. In premenopausal women 13.25%
and in postmenopausal women 9.4% of the patients
fulfilled the criteria of hyperandrogenemia.
For descriptive statistics, we performed ANOVA
in case of normally distributed continuous variables
or c2-tests in case of discrete outcomes to compare
differences between quintiles (Table 1).
Spearman rank correlations were calculated for the
univariate associations between testosterone and CV
risk factors (data not shown).
Univariate and multivariate models were applied
adjusting in different models for baseline age, BMI,
smoking, IGF1 and albumin, menopausal status,
physical activity, alcohol use, hypertension, hyperlipi-
demia, and diabetes mellitus as appropriate (Table 2).
Cox proportional hazards regression models were per-
formed to analyze the relationship between testosterone
and all-cause mortality and CV events (Tables 3 and 4).
Unadjusted and adjusted (for age, BMI, and smoking)
Kaplan–Meier survival curves contrast survival over time
between testosterone quintiles Q2–Q5 versus Q1 (Fig. 2).
Data were analyzed using the statistical software
SAS (Version 9.2, SAS Institute Inc., Cary, NC, USA).
All P values presented are two tailed; P!0.05 was
considered statistically significant.
This manuscript was written in accordance with
the STROBE statement, giving guidelines for reporting
observational studies (23).Results
At baseline, the age of the study population was
57.96G14.37 (meanGS.D.) years, with a mean height
of 163.6G6.50 cm, a mean weight of 71.49
G14.22 kg, and a mean BMI of 26.71G5.17 kg/m2.
Out of 2914 women, 1394 were postmenopausal
and 1185 were premenopausal (with unknown status
for the remaining 335 women).www.eje-online.org
Table 1 Patients’ characteristics in relation to testosterone quintiles (Q1–Q5) at baseline 2003. Values are expressed as geometric means
or numbers. Reported P values according to ANOVA or c2-tests.
Testosterone quintiles
Q1 Q2 Q3 Q4 Q5 P value
Age
Age, years (mean) 62.5 60.5 58.1 55.3 53.5 !0.001
Postmenopausal women (n) 315 311 284 258 226 !0.001
Anthropometric parameters
Weight, kg (mean) 70.0 71.7 72.0 71.2 71.9 NS
Height, cm (mean) 162.6 163.3 163.9 164.1 164.2 0.0003
Waist circumference, cm (mean) 90.8 91.6 90.5 89.5 90.0 NS
Hip circumference, cm (mean) 104.3 105.5 105.3 104.2 104.3 NS
WHR (mean) 0.87 0.87 0.86 0.86 0.86 NS
WHtR (mean) 0.56 0.56 0.55 0.55 0.55 0.025
BMI, kg/m2 (mean) 26.7 27.2 26.9 26.6 26.7 NS
Risk factors
Systolic blood pressure, mmHg (mean) 133.5 133.6 132.3 131.2 129.7 0.008
Diastolic blood pressure, mmHg (mean) 79.4 79.7 80.1 78.8 79.2 NS
Mean blood pressure, mmHg (mean) 105.9 106.0 105.9 104.6 104.2 NS
Total cholesterol, mg/dl (mean) 230.7 228.7 231.7 222.3 230.7 !0.001
LDL cholesterol, mg/dl (mean) 129.6 128.3 131.4 124.5 126.0 0.009
HDL cholesterol, mg/dl (mean) 60.7 60.6 60.8 60.4 57.9 NS
Triglycerides, mg/dl (mean) 144.9 139.8 133.7 125.9 128.8 0.002
Fasting plasma glucose, mg/dl (mean) 96.2 100.9 101.0 98.8 101.0 NS
HbAlc, % (mean) 5.5 5.6 5.6 5.5 5.5 0.041
Biomarkers
Albumin, g/dl (mean) 4.4 4.5 4.5 4.5 4.5 !0.001
IGF1, ng/ml (mean) 117.6 120.5 125.1 134.9 140.6 !0.001
Testosterone, ng/ml (mean) 0.16 0.29 0.41 0.55 1.43 !0.001
Behavioral variables
Physical activity,O2 h/week (n) 273 292 283 276 270 NS
Current smoker (n) 39 52 71 92 93 !0.001
Cigarets per day (current smokers) (mean) 16.2 13.6 12.1 12.8 13.4 0.03
Current alcohol drinkers (regular/daily) (n) 13 20 25 24 13 0.04
Numbers of drinks per week (mean) 2.06 2.09 2.03 2.35 2.26 0.01
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teristics with regard to testosterone levels in quintiles
(Q1–Q5). Using ANOVA and c2-tests for binary
variables, we found that women with low testosterone
levels were significantly older and more likely to be
postmenopausal. Arithmetic means of anthropometric
measures were not significantly different between the
quintiles Q1–Q5 besides a higher WHtR in the lower
testosterone quintiles.
Significant differences between testosterone quintiles
were additionally found for SBP, total cholesterol,
LDL-C, triglycerides, HbAlc, albumin, IGF1, as well as
alcohol drinking and smoking status. Mean DBP, mean
blood pressure, HDL-C, fasting glucose, and physical
activity were not differently distributed between
testosterone quintiles.
Spearman correlations between testosterone with CV
risk factors revealed negative correlations of testoster-
one with age, menopausal status, waist-to-hip ratio
(WHR), WHtR, SBP, mean blood pressure, total
cholesterol, HDL-C, triglycerides, HbAlc, and smoking
status as per cigarettes per day (data not shown).
Significant positive correlations for total testosterone
were found for height, albumin, IGF1, and alcoholwww.eje-online.orgconsumption as per numbers of drinks per week
(data not shown). As expected, IGF1 was highly
correlated with many of the risk factors under
investigation (18).Total testosterone in relation to CV risk factors
and incident CV diseases during the follow-up
period
In prospective analyses, we excluded patients with the
respective prevalent CV risk factor or disease at baseline
as appropriate. Subsequently, we calculated the inci-
dences of CV risk factors (adverse anthropometric
measures, hypertension, hyperlipidemia, T2DM, and
MS) and CV diseases (CAD, MI, and stroke) during the
follow-up period of 4.5 years.
Table 2 reports on the odds ratios (ORs) for newly
diagnosed CV risk factors and diseases with respect to
baseline testosterone levels stratified in quintiles. In
unadjusted models, we observed lower incidences of
hypertension in patients with testosterone levels in
quintiles Q2, Q3, Q4, and Q5 or collapsed Q2–Q5
compared to Q1 at baseline (P for trendZ0.0370).
The incidence of being overweight was higher in Q2
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Q2–Q5 versus Q1 (P for trendZ0.0055). However, further
adjustments abolished these effects indicating a strong
confounding effect of age and BMI for hypertension.
Additional analyses adjusting for the presence of
disease at baseline rather than exclusion of patients
with prevalent diseases were largely confirmatory of the
analyses presented herein.
When analyzing the predictive value of testosterone
levels for incident CV morbidity (CAD, MI, and stroke),
crude analyses and further adjustments (for age, BMI or
smoking or age, BMI, smoking, physical activity, IGF1,
and albumin and where applicable diabetes, hyperten-
sion, and hyperlipidemia) led to non-significant results
of all three investigated outcomes (CAD, MI, and stroke)
(Table 2). Additional analyses adjusting for baseline
diseases rather than exclusion of patients with
prevalent diseases were largely confirmatory of the
analyses presented herein.Total testosterone in relation to all-cause
mortality and CV events during the follow-up
period (HR)
To evaluate independent associations of total testoster-
one with all-cause mortality (Table 3) and any CV
events (Table 4) before and after adjusting for age, BMI,
and smoking, and for age, menopausal status, BMI,
WHR, SBP, LDL-C, HDL-C, triglycerides, HbAlc, albu-
min, alcohol, and smoking, and for age, menopausal
status, BMI, WHR, SBP, LDL-C, HDL-C, triglycerides,
HbAlc, albumin, alcohol, smoking, and antihyperten-
sive treatment, we performed Cox proportional hazard
regressions.
Patients with testosterone levels in the lowest quintile
Q1 (testosterone !0.237 ng/ml) had a higher risk of
death from any cause within the follow-up period of 4.5
years compared with patients in Q3, Q4, or Q5 and the
collapsed quintiles Q2–Q5 in crude and adjusted models
(Q2–Q5 versus Q1: crude HR 0.49, 95% CI 0.33–0.74;
adjusted HR 0.62, 95% CI 0.42–0.939) (Table 3).
Similar results were found for CV events in crude
and adjusted models (Q2–Q5 versus Q1: crude HR
0.54, 95% CI 0.38–0.77; adjusted HR 0.68, 95% CI
0.48–0.97) (Table 4).
In sensitivity analyses, these results were also
confirmed collapsing Q3–Q5 contrasted against Q1 or
Q1CQ2 (data not shown).
We further investigated the importance of prevalent
diseases on the association between testosterone and
mortality as previously described (22). Therefore, we
excluded women with prevalence of diabetes mellitus
(nZ455), CV diseases (nZ276), and cancer (nZ97)
at baseline.
The adjusted HR for all-cause mortality and CV
events remain significantly lower for patients in
quintiles Q2–Q5 compared with women in Q1 if patients
with diabetes mellitus (PZ0.03 and 0.016 respectively)www.eje-online.org
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www.eje-online.organd cancer (PZ0.007 and 0.038 respectively) were
excluded (Tables 3 and 4). However, when CAD at
baseline was excluded, significance for both all-cause
mortality and CV events was reduced to a marginal level
(PZ0.087 and 0.076 respectively).
In additional sensitivity analyses, we excluded female
patients on oral contraceptives or postmenopausal
hormone therapy and hyperandrogenemia including
interaction models with similar outcomes as described.
Figure 2 presents the cumulative survival curves for
subjects in the testosterone lowest quintiles Q1 with
higher all-cause mortality and CV events compared to
female patients in quintiles Q2–Q5 (Fig. 2).Discussion
In this large prospective cohort study, we investigated
the predictive value of total testosterone on the
incidence of CV risk factors, CV diseases, and mortality
in female primary care patients in Germany.
The main finding of our study was the observation
that all-cause mortality and CV events in female
patients with low testosterone levels (Q1, testosterone
!0.237 ng/ml) are elevated compared with patients
with testosterone levels in quintiles Q2–Q5, and that
this association is largely independent of traditional risk
factors. However, no significant prospective associations
were found in unadjusted and adjusted analyses in
relation to new onset, incident, CV risk factors and CV
diseases, implying that, if any, the main association of
low testosterone could be not so much with disease
occurrence but with disease progression, severity,
and/or outcome. Our observational study, albeit pro-
spective and incorporate the time sequence criterion for
causality, cannot prove causality. Two hypotheses might
explain our findings: i) low testosterone in women may
cause or worsen disease and therefore leads to increased
mortality rates or ii) low testosterone is simply a marker
of disease or poor health.
The first hypothesis may be supported by prior
clinical observations in men. Several epidemiological
studies in men have demonstrated that low testosterone
is associated with higher prevalence and incidence of
CV risk factors, CV diseases, and mortality (17, 24, 25).
This phenomenon could be mediated through adverse
direct and indirect effects of low testosterone on
vascular tone, lipid and glucose metabolism, and the
hemostatic system (25). In women, however, conse-
quences of low testosterone or androgen deficiency
on CV risk factors and diseases are poorly studied.
Miller (26), for instance, reviewed that physiological
testosterone replacement in women shows a positive
effect on the restoration of a normal body composition,
however, not consistently (27).
The second hypothesis is that low testosterone is a
marker of poor health or more severe disease. This
hypothesis is supported by pathological findings that
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levels, which is, again, more comprehensively studied in
men (28). It has been hypothesized that the stress
following acute or chronic diseases with subsequent
hypercortisolism may exert direct inhibitory effects on
the hypothalamic–pituitary–gonadal system, resulting
in hypogonadism. In women, it is known that a state of
hypogonadotropic hypogonadism is not only associated
with reduced estrogen, but also associated with lower
testosterone levels (29).
Mohamad et al. (30), Dobrzycki et al. (31), Pugh et al.
(32), and other authors reported that in men,
specifically, CV diseases such as CAD are associated
with hypoandrogenemia, but the results for women are
less well studied and/or conclusive (30–34).
Another argument for the described hypothesis is
supported by our results presented in Table 4. The
exclusion of patients with prevalent CV diseases and
prevalent CV disease or diabetes mellitus or cancer (but
not prevalent diabetes mellitus alone or cancer alone)
attenuated the statistical significance for all-cause
mortality and CV events. We can therefore hypothesize
that low testosterone is not only a marker of poor
health, in general, but also more specifically and
perhaps mainly of CV morbidity and mortality.
Other than stress, underlying diseases causing low
testosterone levels in women are oophorectomy, adrenal
insufficiency, supraphysiologic glucocorticoid adminis-
tration, GnRH administration, anorexia nervosa, or
AIDS wasting. Although the prevalence of patients with
these diseases in our cohort is apparently extremely low,
nevertheless they might have contributed to higher
death rates due to the underlying disease independently
of low testosterone levels.
To our knowledge, this is the most comprehensive
study on this topic in a sample that includes both pre-
and postmenopausal women. Only one smaller scale
epidemiological study in 651 postmenopausal women
investigated mortality over 19 years of follow-up period
in relation to testosterone levels (16). The authors’
comparisons of baseline total and bioavailable testoster-
one levels between female patients who died from CV
disease and those who did not revealed lower baseline
testosterone levels in the first group compared with the
second group, which would be in line with our results.
Differences with respect to significance of HR among
this and our study could be due to differences in the two
population samples (with both pre- and postmenopau-
sal women included in our cohort with a lower mean
age (57.9 versus 66.7 years)) and higher patient
numbers (nZ2914 versus nZ651) despite fewer years
of follow-up period, which might have raised the power.
Additionally, a very recent paper by Laughlin et al. (14)
reported that low levels of testosterone are associated
with an increased risk of coronary heart disease (CHD)
events prospectively, which additionally underlines our
findings (14).www.eje-online.org
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Figure 2 Unadjusted and adjusted (for age, BMI, and smoking)
Kaplan–Meier curves for all-cause mortality (A and B) and any
cardiovascular event (C and D). The graphs represent the
cumulative survival of women in the lowest testosterone quintile Q1
compared to quintiles Q2–Q5.
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www.eje-online.orgStrengths and limitations
Testosterone measurements were performed using an
electrochemiluminescence immunoassay (Elecsys
system, Roche). This technique has been used as the
standard to date and has been calibrated against the
GC–MS technique showing a strong positive correlation.
Ding et al. (8), Patel et al. (13), and Laughlin et al. (14)
recently reported reliable results on testosterone in
women with the immunoassay-based technique.
Our results are based on a single testosterone
measurement. Despite circadian and other variability
of testosterone levels, prior studies have demonstrated
that intra-individual variance of total testosterone is
small and similar in female patients with hyperandro-
genemia or normal testosterone levels, and the authors
propose that single androgen measurements are
legitimate means to determine androgen status (35).
Moreover, any misclassification would be random
and would have suppressed effect estimates toward
the null. Not taking the time of the menstrual cycle for
premenopausal women into account might even further
underestimate true relationships. We neither studied
the role of free testosterone, SHBG, or estradiol nor their
possible interactions with total testosterone. This is
noteworthy, since independent associations of low
SHBG, for instance, with the MS and CV risk factors in
women with PCOS have been reported (36–38).
On the other hand, previous studies found similar
risks for total and free testosterone levels and CV risk
factors in women.
To minimize measurement errors of the outcome and
covariates, data checks for plausibility and completeness
were implemented at data entry to further guarantee
data quality. Potential confounders were addressed by
adjustments for traditional clinical risk factors. Time
differences occurred in the follow-up period between
individual subjects and could have created non-
differential misclassification, which from the statistical
point of view would have resulted in a suppression of
effect estimates and loss of statistical significance.
However, the fact that our results are significant indi-
cates that our methods and statements should be valid.
To avoid confounding by those patients with
extremely elevated testosterone levels, possibly associ-
ated with pathological conditions such as androgen-
producing ovarian and adrenal neoplasms, Cushing’s
syndrome, polycystic ovary syndrome, and the intake of
exogenous androgens, we repeated all analyses exclud-
ing those patients with pathological testosterone values
above 0.82 or O0.59 ng/ml (according to the Rotter-
dam criteria Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group). In the second step, we
excluded all patients on hormonal substitution. In
addition to age, we also stratified and adjusted for
menopausal status (including interaction models).
Since we observed similar results, we decided to report
on all women in DETECT.
Testosterone and mortality in women 707EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163Although a stratified sampling scheme was used
to recruit the patients in DETECT, the population
under investigation reflects a primary care sample and
the results may not be generalizable to the general
German population.
Additionally, our study cohort consists of mainly
relatively older women. The results and conclusions
may therefore not be generalizable to a younger female
population. Why we did not observe significant results
for incident CV risk factors and diseases despite
significant results for the Cox regression analysis on
mortality needs to be discussed. We excluded respective
prevalent risk factors and diseases in the logistic
regression analyses (Table 2), which might have led to
relatively low cases for the follow-up period and might
have underpowered the study for these outcomes. On
the other hand, it is conceivable that testosterone is
rather a marker of progression to and/or indicator of
serious disease and death than of the simple occurrence
of CV diseases, which would be consistent with our
second hypothesis as discussed above.
In conclusion, this study shows in a large primary care
cohort that low baseline testosterone in relatively older
women is associated with increased all-cause mortality
and CV events, which is largely independent of
traditional risk factors. Our results support the notion
that the hormonal status of relatively older women might
have consequences in relation to CV risk and the
diagnostic work-up in women at risk for CV disease.
Future studies are needed to confirm these results, to
explore underlying mechanisms, and to determine
whether this finding may prove to have direct impli-
cations on the clinical management of these patients.Declaration of interest
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